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Abstract
Introduction: Children with inflammatory bowel disease (IBD) often require infliximab infusions to manage their disease.
Infusions administered in the hospital setting require the patient and their families to devote many hours away from home.
Changing to a rapid infusion protocol has been shown in the literature to be safe and has the potential to decrease time spent in
the hospital receiving infusions. Methods: We describe stepwise changes made over a 4-month period to improve infliximab infusion efficiency and lessen the time spent in the hospital by IBD patients and their families. These changes included the implementation of a standardized order set, defaulting to rapid infusions for eligible patients, eliminating the post-infusion observation
window, and improving the pharmacy's efficiency in preparing infusion medications. We utilized several established quality
improvement tools, including a smart aim, key driver diagram, plan-do-study-act cycles, and statistical process control charts
to measure these interventions. Results: Within three months of starting, the average door-to-door time patients spent in the
hospital decreased by 128 minutes (2 hours 8 minutes). This improvement amounts to 768 minutes (12 hours 48 minutes) per
year of time returned for normal childhood activities outside of the hospital. There were no infusion reactions during the period
monitored. Conclusions: Implementation of a rapid infliximab infusion protocol made an impressive impact on freed family time
without sacrificing patient safety. The changes we implemented could be helpful to other centers interested in decreasing in-hospital time for patients with IBD and their families. (Pediatr Qual Saf 2019;4:e131; doi: 10.1097/pq9.0000000000000131; Published
online January 21, 2019.)

INTRODUCTION

manage their disease adequately. A common and effective
biologic used for this purpose is infliximab, a chimeric
monoclonal antibody against tumor necrosis
factor-α. Time spent receiving these infusions in the hospital setting disrupts school,
extracurricular activities, time spent
at home, and other aspects of normal
childhood development. Hospital-based
infusions also expose patients to nosocomial pathogens and potential infection.
Significant nursing time can also be spent
in hospital-based infusions, tying up needed
hospital resources.
Because infliximab is a biologic medication,
its administration carries a small risk of a severe hypersensitivity reaction including anaphylaxis.1 There is variation in infliximab administration practices in the United
States.2 However, there is good evidence in the literature
demonstrating that rapid infliximab infusions 60 minutes
in duration are safe after a child has reached the maintenance phase of his treatment with no prior symptoms
of an infusion reaction.3–5 Shorter infusions may be safer
according to the results of a Canadian study from 2011.6
The goal of this quality improvement (QI) project was
to implement a standard practice in a Midwestern children’s hospital in which all eligible IBD patients would
receive rapid infliximab infusions with a standardized
process, thereby decreasing the average time spent at the
hospital by patients and their families. We also hoped to
simultaneously improve patient quality of life, patient
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satisfaction, and the efficiency of health care delivery,
though we did not formally asses these metrics. If this
intervention were to be adopted broadly, it could substantially decrease the cumulative hours children with IBD
and their families spend receiving infusions in hospital
settings nationwide. An executive sponsor supported the
project, and it was completed as part of the Intermediate
Improvement Science Series, supported by Cincinnati
Children’s Hospital Medical Center.

An interdisciplinary team consisting of 5 pediatric gastroenterologists, a gastroenterology nurse, an infusion
nurse educator, an infusion nurse, a clinical pharmacist,
a QI consultant, and an executive sponsor began meeting in July 2014 to address this project specifically. The
QI framework was implemented to create a smart aim:
to decrease the average door-to-door time for eligible
children to receive rapid infliximab infusions from 279
minutes (4 hours 39 minutes) to 137 minutes (2 hours
17 minutes) over a 6-month period (Fig. 1). We set this
goal from best case scenario modeling plus a 10% buffer.
We define door-to-door time as when patients are registered to when they have been discharged; both were time
stamped in the electronic medical record (EMR) and
manually extracted. We identified key drivers and populated corresponding interventions, presented in an interim
key driver diagram, complete with SMART (Specific,
Measurable, Actionable, Relevant, Time-bound) aim (Fig.
1). Plan-do-study-act cycles (PDSAs; Fig. 2) which are an
iterative, problem-solving modeling tool commonly used
in QI work, allowed the team to learn from early failures
and successes and provided a framework for spreading
successful changes.

METHODS
We undertook this project in a medium-sized free-standing children’s hospital in the Midwest. In our institution at
the project’s inception, 5 physicians cared for patients with
IBD). Our population of patients with IBD slowly increased
throughout this project, given patients were newly diagnosed, and incorporated into our data collection. At the
beginning of the project, our population consisted of approximately 140 IBD patients, with approximately 50 receiving infliximab infusions, and 28 eligible for rapid infusions (RIs) based on our protocol. These patients received
infusions every 4–8 weeks, depending on clinical dictate.

Fig. 1. KDD, including SMART (Specific, Measurable, Actionable, Relevant, Time-bound) aim. EMR indicates electronic medical record; KDD, key driver diagram; LOR, level of reliability.
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RESULTS

Chart reviews, confirmed with direct clinical observation, provided overall door-to-door times and interval
steps of a typical patient’s infusion visit including registration, medication preparation, preinfusion nursing assessment, preinfusion preparation, infusion, postinfusion
observation, and discharge (see Pareto chart, Fig. 3A).
The Pareto chart guided the team toward those steps in
the process (primarily the times of infusion and postinfusion observation) where we could attain the largest
improvements.
Previous research has shown that RIs are safe.3,6 A primary intervention of this project included the transition
of eligible patients to RI to decrease door-to-door times
in the hospital. To be eligible, patients needed their first 3
induction infusions plus 1 maintenance infusion complete
without any evidence of an infusion reaction.3 Written
handouts were given to families in the form of letters, and
discussed with families in the clinic setting and at infusions
via standardized scripting before making the transition.
We trained nurses and physicians to use the standardized
scripting before transitioning patients. Patients, families, or
medical treatment teams could opt out of RIs at any point
throughout this QI project for safety or any other concerns.
We describe interventions in the Results section below.
We gathered data to assess the efficiency and safety of
the new process. The primary outcome measure was
the door-to-door infliximab infusion times within the
observation unit of the hospital. We used Microsoft
PowerPoint, Excel, and Word to create a smart aim,
key driver diagram, PDSA ramps, simplified failure
mode effects analysis (Supplementary Digital Content 1,
Figure 1, http://links.lww.com/PQ9/A66), statistical process control charts, and other tools that aided in data
analysis, interpretation, and communication among
target populations.
The changes above were implemented initially on a
small scale, and each analyzed within a PDSA framework. We made slight adjustments through several tests
of change, at each iteration gaining more momentum
and buy-in for broader application. We created a control
chart with the data collected on door-to-door times before the project initiation (ie, for baseline data), during
each test of change, and throughout the maintenance
phase covering a 6-month period (Fig. 4). Each data point
in Fig. 4 represents the measured minutes of a single infusion visit. After the 6-month period ended, data were
collected on a less frequent basis (via a standard sampling frame) to ensure stability and to ensure that we
sustained gains.
There were no anticipated ethical concerns before starting this QI initiative, nor did we uncover any throughout.
There were no conflicts of interest. Our local institutional
review board approved this project as being a nonresearch,
QI initiative, and thus did not undergo a full committee
review. We employed SQUIRE (Standards for QUality
Improvement Reporting Excellence) 2.0 Guidelines in the
creation of this article.

Within 2 months of testing the standard order set, eliminating a postinfusion observation period (EO), and
transitioning those eligible patients to RIs, the average
door-to-door time decreased from a mean of 279 minutes (4 hours 39 minutes) to 202 minutes (3 hours 22
minutes), just 65 minutes longer than the initial SMART
aim goal. One month later, following 2 more PDSAs, including broader application, the average door-to-door
time decreased further to 151 minutes (2 hours 31 minutes), only 14 minutes longer than the smart aim goal
(Fig. 4). We have sustained these improvements over
multiple years.
An examination of the time obtained for each step of
the new infusion process is presented in a Pareto chart
as Fig. 3B. These data were taken from a sampling of 3
patients in October 2018 and demonstrates gains in virtually all steps of the process.
Using the difference in means from the control chart,
we determined that these changes saved roughly 13 hours
of nursing time each week. This time saved allowed for
46% more time for infusion patients. Even more importantly, these changes allowed for 128 minutes (2 hours 8
minutes) of freed family time. An additional benefit included less administration time spent in order placement
through the use of a standard order set. We estimate that
120 hours were spent in planning, undertaking PDSAs,
data analysis, and implementation efforts.
Concerning balancing measures, there were no adverse events, including no infusion reactions, in patients
who received RIs during data collection. We received no
reports of decreased quality or safety concerns from families or staff. Review of office visit documentation after RIs
revealed no safety or quality concerns, including those
items listed above.

Interventions

The initial change in moving toward rapid infliximab
infusions involved creating a standardized order set
within the institution’s EMR. The goal of this order set
was to simplify the process of placing infliximab infusion
orders for the gastroenterologists on staff and making
the orders more standardized regardless of provider. The
typical dosing of medications (including premedications
and infliximab), the infusion rate, and the multitude of
nursing orders were all included. The order set made the
front-end work more efficient and also supported the upcoming change toward RIs. The specific orders for each
patient became more standardized and could be better
anticipated by the infusion nursing staff as they prepared
for the visit and cared for the patients throughout their
infusions.
The next change was 2-fold: transitioning all eligible
patients to RIs and eliminating the 30-minute postinfusion EO. The RI meant cutting the actual infusion time
in half from 120–60 minutes. This change, plus the EO,
meant 90 minutes of the door-to-door time would be
3
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Fig. 2. Plan-do-study-act (PDSA) cycles. A, Sample PDSA worksheet for the transition to rapid infusion. B, PDSA Ramp: transition
eligible patients/default to rapid infusions. IFX, Infliximab; GI, Gastroenterology.
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Fig. 3. Pareto charts of door-to-door time spent by families who receive infliximab infusions at the start of the project in July 2014 (A)
and in October 2018 (B). DCH, Dayton Children’s Hospital; IFX, Infliximab.
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Fig. 4. Statistical process control chart with annotations. EO indicates eliminate observation; RI, rapid infusion start; SOS, standardized order set.

reduced via this change alone. We had no infusion reactions in the preceding 2 years before the start of this QI
project.
Four months from the start of the project, an additional
change was made within the institution’s pharmacy to improve the efficiency of infusion preparation and further
reduce the average patient door-to-door time. The pharmacy built a physical pass-through window in the wall
adjacent to the infusion medication preparation area.
Before this change, pharmacy technicians would have to
don and doff personal protective equipment, sometimes
repeatedly, during the preparation of an infliximab infusion if items needed were forgotten outside that room.
After this change, other pharmacy staff could easily hand
a needed item through the pass-through window to the
technician preparing the infusion, thus making the entire
process more efficient.

to improved efficiency and familiarity with the new
protocol. The 2 hours 8 minutes of freed time could be
returned to the patients and their families. For a patient
who receives 6 infliximab infusions per year, a total time
savings of 768 minutes (12 hours 48 minutes) per year
could be amassed. Children with chronic disease spend
more time in healthcare settings (emergency department,
primary care, specialty clinics, and hospitals), and their
care represents a substantial financial burden, than compared with those without a chronic disease.7–11 This reality impacts home life, school life, developmental aspects,
and social growth. By returning this time to patients and
their families, we give back a part of childhood stolen
by IBD. Further steps toward a home-based or external-based infusions would further improve quality of life,
and efforts are currently underway across the country to
ensure this is done safely.12
As with most changes, there is often resistance at the
start. We found that reminding the physicians to utilize
the new order set, familiarizing nursing staff with changes
in their orders, and getting the pharmacy involved in more
efficient infusion preparation were all challenges initially.
The culture change toward default RIs was surprisingly
quick, however. Even with standardized scripting and adequate forewarning for patients’ families, there was still
some hesitation, given concern for infusion reactions. The

DISCUSSION
This study showed a statistically significant decrease in
average door-to-door times for patients receiving infliximab infusions in a children’s hospital observation unit.
The initial 90-minute decrease was expected given the
shorter infusion time and omitting the postinfusion EO.
There were an additional 38 minutes of time saved thanks
6
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Nancy Severt, RPh, the director of the pharmacy, who
oversaw the pass-through expansion; and Brenda Lee,
the quality improvement coach from Intermediate
Improvement Science Series.

standardized scripting was thought to help prevent unintended variation in the initiatives, and improve communication between families and care teams.
This QI effort has several important limitations. First,
we collected multiple data by hand. All attempts were
made to ensure data accuracy, but there remains a possibility of human error. Second, we were reliant on our
EMR for the timing of entries. Multiple reasons could
have delayed a patient before their first official entry into
our system, and evaded capture in our recording of data.
Third, this was a project at a single center, which may
compromise external validity. Smaller institutions tend to
have less representation in the medical literature, however, and we felt the lessons learned here could be generalizable to other smaller institutions and also applicable
to larger pediatric facilities.
We want to emphasize that this project did not reveal
any patient safety concerns after adopting a RI protocol.
A study at Stanford in 2017 yielded no safety concerns
over a 2-year period of rapid infliximab infusions.13
Implementation of rapid infliximab infusion protocols
nationwide could result in a considerable amount of
freed time for IBD patients. Our QI work at a smaller
free-standing children’s hospital suggests rapid improvement is possible with small sustained efforts. Our return on investment is roughly 1 hour invested for 1 hour
returned for every 10 patients. In our eligible population
for RIs, this equates to a 7-fold return of time for every
hour of medical team investment.
Implementing a rapid infliximab infusion protocol at
our institution was associated with decreased average
door-to-door times for patients with IBD and their families, thus freeing up patient time for activities outside
the hospital and improving the efficiency of health care
delivery. We continue to look for ways to improve the
quality of life for children with chronic disease.
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